Pfizer COVID-19 vaccine safety data - Pregnant participants COVID-19 vaccines Main navigation COVID-19 vaccines All participants Aboriginal and Torres Strait Islander participants Adolescent participants People affected by cancer and transplant recipients Pregnant participants Influenza vaccines National Immunisation Program Schedule vaccines Data on this page show the responses of pregnant individuals who received the Pfizer COVID-19 vaccine and completed an AusVaxSafety survey sent on day 3 after vaccination. These data provide you with a profile of what to expect in the days following your Pfizer COVID-19 vaccination and can assist when planning for your COVID-19 vaccination. Reporting pause over upcoming holiday period, read more here. The profile of reported events from AusVaxSafety surveillance of the Pfizer (Comirnaty) COVID-19 vaccine is similar to that reported in clinical trials and from post-marketing surveillance overseas. AusVaxSafety's active vaccine safety surveillance system complements the TGA's enhanced safety surveillance activities. Find out more about how the TGA monitors the safety of COVID-19 vaccines and how you can report side effects on the TGA website. Read more about how AusVaxSafety is conducting national COVID-19 vaccine safety surveillance in Australia here. Links to further information on the expected profile for the Pfizer (Comirnaty) COVID-19 vaccine are available below: Australian Technical Advisory Group on Immunisation (ATAGI) clinical guidance on use of COVID-19 vaccine in Australia in 2021 Guidance on Myocarditis and Pericarditis after mRNA COVID-19 vaccines Comirnaty vaccine phase III trial publication Comparison of Comirnaty and COVID-19 AstraZeneca vaccines in United Kingdom publication AusVaxSafety will continue to closely monitor the safety data of all COVID-19 vaccines in use in Australia in conjunction with the TGA.